SynthesisDigestive diseases and sciences2026
Clinical Outcomes of Acute Pancreatitis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Systematic Review and Meta-Analysis.
Synthesis in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) is being increasingly identified in patients with acute pancreatitis (AP). However, their prognostic significance remains debatable.
objectiveWe conducted a systematic review and meta-analysis to examine the association between MAFLD and the clinical outcomes of AP.
methodsComprehensive searches were conducted in the PubMed, Embase, Web of Science, Cochrane Library, Scopus, and Ovid databases up to June 2, 2025. This analysis included observational studies that compared acute pancreatitis (AP) outcomes in patients with and without metabolic-associated fatty liver disease (MAFLD). Pooled odds ratios (ORs), mean differences (MDs), and 95% confidence intervals (CIs) were calculated using fixed or random-effects models depending on the heterogeneity observed. Subgroup and sensitivity analyses were also performed.
resultsA total of ten studies involving 6,436 patients were analyzed. Patients with metabolic-associated fatty liver disease (MAFLD) had a significantly higher risk of severe acute pancreatitis (Odds Ratio [OR] = 1.86), organ failure (OR = 1.65), and in-hospital mortality (OR = 1.71) than those without MAFLD. Additionally, MAFLD was linked to greater local complications and more extended hospital stay. Sensitivity and subgroup analyses confirmed the reliability of these findings.
conclusionMetabolic-associated fatty liver disease (MAFLD) is associated with poor clinical outcomes in patients with acute pancreatitis (AP), including increased severity, complications, and mortality rates. These findings indicate that MAFLD should be incorporated into the clinical risk stratification and management strategies for AP.
Indexed as
Identifiers
40813520What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.